Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | TGFB1 | P01137 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250068 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248684 | 0.89 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL19492162 | 0.88 | TGFBR1 (0.78) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL16542421 | 0.88 | TGFBR1 (0.78) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL249118 | 0.87 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL3439088 | 0.87 | TGFBR1 (0.81) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248723 | 0.86 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL250076 | 0.86 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29352498 | 0.86 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29493095 | 0.86 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47141-E1 | Methods of treating fibrosis, cancer and vascular injuries | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-27 | — | — | US | claimed |
| US-RE47122-E1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-13 | — | — | US | claimed |
| EP-2588479-B3 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-03-29 | — | — | EP | claimed |
| EP-2947081-A1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | Ewha University-Industry Collaboration Foundation (KR) | 2015-11-25 | — | — | EP | claimed |
| EP-2588479-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | UNIV EWHA IND COLLABORATION (KR) | 2015-03-04 | — | — | EP | claimed |
| US-8513222-B2 | Methods of treating fibrosis, cancer and vascular injuries | EWHA University—Industry Collaboration Foundation (KR) | 2013-08-20 | — | — | US | claimed |
| EP-2588479-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | Ewha University-Industry Collaboration Foundation (KR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012002680-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-01-05 | — | — | WO | claimed |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | claimed |
| US-20110319408-A1 | Methods of Treating Fibrosis, Cancer and Vascular Injuries | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | claimed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | claimed |
| US-RE47141-E1 | Methods of treating fibrosis, cancer and vascular injuries | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-27 | — | — | US | disclosed |
| US-RE47122-E1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-2947081-B1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-10-18 | — | — | EP | disclosed |
| EP-2947081-B1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-10-18 | — | — | EP | disclosed |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | disclosed |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | disclosed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319408-A1 | Methods of Treating Fibrosis, Cancer and Vascular Injuries | ACVR1, FLT4, TEK | TGFBR1 8/4885MAPK14 2575/4885RIPK2 1071/4885 |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | ALK, ACVR1, ACVRL1 | TGFBR1 4/4885MAPK14 776/4885RIPK2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.